SEC Form 4 · accession 0001161697-26-000171
CATALYST PHARMACEUTICALS, INC. · CPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William T. Andrews
Officer — Chief Medical Officer
Period of report
Jul 15, 2026
Accepted (ET)
Jul 17, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001369568
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.001 per share | Jul 15, 2026 | D | 2,309 | $31.50 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to purchase common stockF5 | $24.90 | Jul 15, 2026 | D | 124,447 | D | — | Jun 2, 2032 | Common Stock | 124,447 | 0 | D |
| Options to purchase common stockF5 | $22.77 | Jul 15, 2026 | D | 98,652 | D | — | Nov 20, 2032 | Common Stock | 98,652 | 0 | D |
| Restricted Stock UnitsF2,F5 | — | Jul 15, 2026 | D | 12,209 | D | — | Jun 2, 2030 | Common Stock | 12,209 | 0 | D |
| Restricted Stock UnitsF2,F5 | — | Jul 15, 2026 | D | 29,776 | D | — | Nov 20, 2028 | Common Stock | 29,776 | 0 | D |
Explanation of responses
- F1The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")
- F2Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
- F4In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
- F5Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.